CSIMarket Company Name, Ticker, Competitors, else..
 
Addex Therapeutics Ltd  (NASDAQ: ADXN)
Other Ticker:  
 
 
Price: $7.3000 $-0.40 -5.195%
Day's High: $7.7 Week Perf: -4.07 %
Day's Low: $ 6.82 30 Day Perf: -0.75 %
Volume (M): 21 52 Wk High: $ 27.90
Volume (M$): $ 155 52 Wk Avg: $9.66
Open: $7.49 52 Wk Low: $6.67



 Market Capitalization (Millions $) 550
 Shares Outstanding (Millions) 75
 Employees 17
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Addex Therapeutics Ltd
Addex Therapeutics Ltd is a biopharmaceutical company that specializes in developing novel drugs to treat diseases of the central nervous system (CNS). The company is headquartered in Geneva, Switzerland and is publicly traded on the SIX Swiss Exchange.

Addex is focused on developing drugs that target the gamma-aminobutyric acid (GABA) system, which plays a critical role in the regulation of nerve cell activity in the brain. By modulating GABA receptors, Addex aims to develop drugs to address various CNS disorders, including Parkinson's disease, migraine, epilepsy, and addiction.

The company has a proprietary technology platform called allosteric modulation, which allows for the discovery and development of drugs that selectively enhance or inhibit specific GABA receptors. This approach offers the potential for more targeted and safer drugs compared to traditional approaches.

Addex's pipeline includes several drug candidates, including dipraglurant for the treatment of Parkinson's disease and levodopa-induced dyskinesia, as well as ADX71149 for the treatment of migraine and epilepsy. These drugs are currently in different stages of clinical development, with some in Phase 2 clinical trials.

In addition to its own drug development programs, Addex also collaborates with pharmaceutical and biotechnology companies to advance its technologies and drug candidates. The company has established partnerships with companies such as Janssen Pharmaceuticals, Indivior, and the National Institute on Drug Abuse.

Overall, Addex Therapeutics Ltd is focused on advancing innovative drugs targeting the GABA system to address unmet medical needs in the field of CNS disorders.


   Company Address: Chemin des Mines 9 Geneva 1202
   Company Phone Number: 884 1555   Stock Exchange / Ticker: NASDAQ ADXN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.31% 
BMY   -0.35%    
LLY        4.41% 
PFE        2.35% 
TEVA        0.33% 
VTRS        3.03% 
• View Complete Report
   



Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp disclosed a stunning -31.675 %, in revenue, during the fourth quarter of 2024

Declining demand caused an increase in deficit for the financial span ending December 31 2024, Tonix Pharmaceuticals Holding Corp s' deficit per share inched up to $-5.41 from $-105.08 where Revenue fell by -31.675 % to $2.58 million from $3.78 million a year ago. The deterioration of revenue is not comparable to relative to all in all Major Pharmaceutical Preparations sector, which posted a top-line growth during the same period.

Kronos Bio Inc

A shortfall of $-0.41 per Share at the Kronos Bio Inc in the fiscal fourth quarter of 2024

For the fiscal fourth quarter of 2024 KRON lost money of $-0.41 per share compare to $-0.42 a year prior and grew shortfall from $-0.23 per share from the prior reporting period. The revenue decreased by -0.7 % to $2.27 million from $2.29 million in the similar reporting period a year prior and sequentially Revenue decreased by -4.219 % from $2.37 million.

Exicure Inc

Working expenses were on the rise at the XCUR in the fourth quarter of 2024 earnings season

Following the large companies in the Major Pharmaceutical Preparations sector, a number of lesser known businesses are publishing the numbers. XCUR revealed it has booked operating shortfall of $-7.589 million, for the fourth quarter of 2024.

Liquidia Corporation

The Top-line plunged at LQDA in the fourth quarter of 2024 earnings season

the Major Pharmaceutical Preparations company declared disappointing Dec 31 2024 report, where Revenue melted down by -35.621 % to $2.92 million and the Liquidia Corporation recorded net loss per share to $-0.39, compared to $-0.42, in the comparable interval a year before. In contrast to the the LQDAs' scenario the remainder ofMajor Pharmaceutical Preparations sector, recorded a revenue 11.88% improvement from the comparable quarter a year ago in the fourth quarter of 2024.

Hutchmed China Limited

The unpleasant -24.797 % fall in revenue at the Major Pharmaceutical Preparations company all along the fourth quarter of 2024 earnings season

Revenue contraction of -24.797 % caused fall in profits by -66.67 % for the financial three months closing Dec 31 2024. HCM posted earnings of $630.20 million in Revenue this compares to $838.00 million a year prior and eps of $0.04 per share from 0.12 in the prior year. On the contrary to the Major Pharmaceutical Preparations company's scenario the all in allMajor Pharmaceutical Preparations industry, posted a revenue 11.88% gain compared to the similar period a year before in the fourth quarter of 2024.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com